Fresenius Medical Care AG / Disclosure pursuant to Art. 5 para. 1 lit. b) of Regulation (EU) No. 596/2014
Fresenius Medical Care AG : Release of a capital market information
06.07.2026 / 16:20 CET/CEST
Dissemination of a Post-admission Duties announcement transmitted by - a service of .
The issuer is solely responsible for the content of this announcement.
Fresenius Medical Care AG: Share buyback
Disclosure pursuant to Art. 5 para. 1 lit. b) of Regulation (EU) No. 596/2014
Share buyback – Interim Report
In the period from June 29, 2026 to July 3, 2026 (each inclusive), 609,595 shares were bought back within the framework of the first tranche of the share buyback of Fresenius Medical Care AG, the start of which was disclosed on May 28, 2026, pursuant to Art. 5 para. 1 lit. a) of Regulation (EU) No. 596/2014, Art. 2 para. 1 of Delegated Regulation (EU) 2016/1052.
Shares were bought back as follows:
| DateAcquired shares (number)Weighted average price (in EUR)Transaction volume (in EUR)Trading venue | 29 June 2026152,00040.29776,125,250.40XETR | 30 June 2026230,00039.47809,079,940.00XETR | 1 July 2026100,00039.77223,977,220.00XETR | 2 July 202685,70240.54843,475,078.98XETR | 3 July 202641,89341.07261,720,654.43XETR |
A total of 2,682,540 shares has been acquired within the framework of the first tranche of the share buyback.
The purchase of the shares is carried out by a credit institution commissioned by Fresenius Medical Care AG.
Fresenius Medical Care AG will provide regular information regarding the progress of the share buyback, including by posting its required disclosures at .
06.07.2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
| Language:English | Company:Fresenius Medical Care AG | Else-Kröner-Straße 1 | 61352 Bad Homburg | Germany | Internet:www.freseniusmedicalcare.com |
| End of NewsEQS News Service |
2361014 06.07.2026 CET/CEST Saving the news in databases or any forwarding of the news to third parties in a commercial context or for commercial purposes is only permitted with the prior written consent of EQS Group AG.